Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.

Thierry André,David Tougeron,Guillaume Piessen,Christelle de la Fouchardière,Christophe Louvet,Antoine Adenis,Marine Jary,Christophe Tournigand,Thomas Aparicio,Jérôme Desrame,Astrid Lièvre,Marie-Line Garcia-Larnicol,Thomas Pudlarz,Romain Cohen, Salomé Memmi,Dewi Vernerey,Julie Henriques,Jérémie H Lefevre,Magali Svrcek

Journal of clinical oncology : official journal of the American Society of Clinical Oncology（2023）

引用 62|浏览42

暂无评分

摘要

Nivolumab and ipilimumab-based neoadjuvant therapy is feasible and associated with no unexpected toxicity and a high pCR rate in patients with dMMR/MSI-H resectable gastric/GEJ adenocarcinoma.

查看译文

关键词

esophagogastric junction adenocarcinoma,localized deficient mismatch repair/microsatellite,neoadjuvant nivolumab,repair/microsatellite instability–high,mismatch repair/microsatellite

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要